PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025

First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy

PulseSight Therapeutics receives CTA approval from ANSM for Phase I trial in France of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

PulseSight Therapeutics Presents New Data on PST-611 Transferrin Vectorized Therapy for Geographic Atrophy at EVER Congress 2024

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

PulseSight Therapeutics reinforces its scientific leadership in ophthalmology with the establishment of an International Scientific and Clinical Advisory Board

PulseSight Therapeutics Confirms H2 2024 Conference Schedule

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases